Cargando…

First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer

In several solid tumors, fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts in the tumor microenvironment. Preliminary evidence suggests that detection and staging are feasible with PET/CT imaging using [(68)Ga]-radiolabeled inhibitors of FAP also in cervical cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Wegen, Simone, Roth, Katrin Sabine, Weindler, Jasmin, Claus, Karina, Linde, Philipp, Trommer, Maike, Akuamoa-Boateng, Dennis, van Heek, Lutz, Baues, Christian, Schömig-Markiefka, Birgid, Schomäcker, Klaus, Fischer, Thomas, Drzezga, Alexander, Kobe, Carsten, Köhler, Christhardt, Marnitz, Simone
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835656/
https://www.ncbi.nlm.nih.gov/pubmed/36607364
http://dx.doi.org/10.1097/RLU.0000000000004505
_version_ 1784868713179119616
author Wegen, Simone
Roth, Katrin Sabine
Weindler, Jasmin
Claus, Karina
Linde, Philipp
Trommer, Maike
Akuamoa-Boateng, Dennis
van Heek, Lutz
Baues, Christian
Schömig-Markiefka, Birgid
Schomäcker, Klaus
Fischer, Thomas
Drzezga, Alexander
Kobe, Carsten
Köhler, Christhardt
Marnitz, Simone
author_facet Wegen, Simone
Roth, Katrin Sabine
Weindler, Jasmin
Claus, Karina
Linde, Philipp
Trommer, Maike
Akuamoa-Boateng, Dennis
van Heek, Lutz
Baues, Christian
Schömig-Markiefka, Birgid
Schomäcker, Klaus
Fischer, Thomas
Drzezga, Alexander
Kobe, Carsten
Köhler, Christhardt
Marnitz, Simone
author_sort Wegen, Simone
collection PubMed
description In several solid tumors, fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts in the tumor microenvironment. Preliminary evidence suggests that detection and staging are feasible with PET/CT imaging using [(68)Ga]-radiolabeled inhibitors of FAP also in cervical cancer (CC). Our study aims to explore the accuracy of [(68)Ga]Ga–fibroblast activation protein inhibitor (FAPI)-46 PET/CT and [(18)F]F-FDG PET/CT compared with histopathological results of surgical lymph node (LN) staging before primary chemoradiation. METHODS: Seven consecutive women with treatment-naive and biopsy-proven locally advanced CC underwent both whole-body [(68)Ga]Ga-FAPI-46- and [(18)F]F-FDG PET/CT, for imaging nodal staging before systematic laparoscopic lymphadenectomy of the pelvic and para-aortic region. Location and number of suspicious LNs in PET imaging were recorded and compared with the results of histopathological analysis, including immunohistochemical staining for FAP. RESULTS: All 7 patients had focal uptake above background in their tumor lesions in [(68)Ga]Ga-FAPI-46 PET/CT. [(68)Ga]Ga-FAPI-46 PET/CT showed a higher tumor-to-background ratio (TBR) in primary tumor as well as in LN metastasis. Median TBR(max) values using liver were 32.02 and 5.15 for [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]F-FDG PET/CT, respectively. Median TBR(max) using blood pool was 18.45 versus 6.85 for [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]F-FDG PET/CT, respectively. Higher TBR also applies for nodal metastasis: TBR(max) was 14.55 versus 1.39 (liver) and 7.97 versus 1.8 (blood pool) for [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]F-FDG PET/CT, respectively. Overall, [(68)Ga]Ga-FAPI-46 PET/CT detected more lesions compared with [(18)F]F-FDG PET/CT. Following surgical staging, a total of 5 metastatic LNs could be pathologically confirmed, of which 2 and 4 were positive by [(18)F]F-FDG PET/CT and [(68)Ga]Ga-FAPI-46 PET/CT, respectively. CONCLUSION: [(68)Ga]Ga-FAPI-46 PET/CT seems useful to improve detection of nodal metastasis in patients with CCs. Future studies should aim to compare [(68)Ga]Ga-FAPI-46 PET/CT to surgical staging of pelvic and para-aortic LNs in patients with locally advanced CC.
format Online
Article
Text
id pubmed-9835656
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-98356562023-01-19 First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer Wegen, Simone Roth, Katrin Sabine Weindler, Jasmin Claus, Karina Linde, Philipp Trommer, Maike Akuamoa-Boateng, Dennis van Heek, Lutz Baues, Christian Schömig-Markiefka, Birgid Schomäcker, Klaus Fischer, Thomas Drzezga, Alexander Kobe, Carsten Köhler, Christhardt Marnitz, Simone Clin Nucl Med Original Articles In several solid tumors, fibroblast activation protein (FAP) is overexpressed by cancer-associated fibroblasts in the tumor microenvironment. Preliminary evidence suggests that detection and staging are feasible with PET/CT imaging using [(68)Ga]-radiolabeled inhibitors of FAP also in cervical cancer (CC). Our study aims to explore the accuracy of [(68)Ga]Ga–fibroblast activation protein inhibitor (FAPI)-46 PET/CT and [(18)F]F-FDG PET/CT compared with histopathological results of surgical lymph node (LN) staging before primary chemoradiation. METHODS: Seven consecutive women with treatment-naive and biopsy-proven locally advanced CC underwent both whole-body [(68)Ga]Ga-FAPI-46- and [(18)F]F-FDG PET/CT, for imaging nodal staging before systematic laparoscopic lymphadenectomy of the pelvic and para-aortic region. Location and number of suspicious LNs in PET imaging were recorded and compared with the results of histopathological analysis, including immunohistochemical staining for FAP. RESULTS: All 7 patients had focal uptake above background in their tumor lesions in [(68)Ga]Ga-FAPI-46 PET/CT. [(68)Ga]Ga-FAPI-46 PET/CT showed a higher tumor-to-background ratio (TBR) in primary tumor as well as in LN metastasis. Median TBR(max) values using liver were 32.02 and 5.15 for [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]F-FDG PET/CT, respectively. Median TBR(max) using blood pool was 18.45 versus 6.85 for [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]F-FDG PET/CT, respectively. Higher TBR also applies for nodal metastasis: TBR(max) was 14.55 versus 1.39 (liver) and 7.97 versus 1.8 (blood pool) for [(68)Ga]Ga-FAPI-46 PET/CT and [(18)F]F-FDG PET/CT, respectively. Overall, [(68)Ga]Ga-FAPI-46 PET/CT detected more lesions compared with [(18)F]F-FDG PET/CT. Following surgical staging, a total of 5 metastatic LNs could be pathologically confirmed, of which 2 and 4 were positive by [(18)F]F-FDG PET/CT and [(68)Ga]Ga-FAPI-46 PET/CT, respectively. CONCLUSION: [(68)Ga]Ga-FAPI-46 PET/CT seems useful to improve detection of nodal metastasis in patients with CCs. Future studies should aim to compare [(68)Ga]Ga-FAPI-46 PET/CT to surgical staging of pelvic and para-aortic LNs in patients with locally advanced CC. Lippincott Williams & Wilkins 2023-02 2022-12-23 /pmc/articles/PMC9835656/ /pubmed/36607364 http://dx.doi.org/10.1097/RLU.0000000000004505 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Original Articles
Wegen, Simone
Roth, Katrin Sabine
Weindler, Jasmin
Claus, Karina
Linde, Philipp
Trommer, Maike
Akuamoa-Boateng, Dennis
van Heek, Lutz
Baues, Christian
Schömig-Markiefka, Birgid
Schomäcker, Klaus
Fischer, Thomas
Drzezga, Alexander
Kobe, Carsten
Köhler, Christhardt
Marnitz, Simone
First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
title First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
title_full First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
title_fullStr First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
title_full_unstemmed First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
title_short First Clinical Experience With [(68)Ga]Ga-FAPI-46-PET/CT Versus [(18)F]F-FDG PET/CT for Nodal Staging in Cervical Cancer
title_sort first clinical experience with [(68)ga]ga-fapi-46-pet/ct versus [(18)f]f-fdg pet/ct for nodal staging in cervical cancer
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9835656/
https://www.ncbi.nlm.nih.gov/pubmed/36607364
http://dx.doi.org/10.1097/RLU.0000000000004505
work_keys_str_mv AT wegensimone firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT rothkatrinsabine firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT weindlerjasmin firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT clauskarina firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT lindephilipp firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT trommermaike firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT akuamoaboatengdennis firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT vanheeklutz firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT baueschristian firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT schomigmarkiefkabirgid firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT schomackerklaus firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT fischerthomas firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT drzezgaalexander firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT kobecarsten firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT kohlerchristhardt firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer
AT marnitzsimone firstclinicalexperiencewith68gagafapi46petctversus18fffdgpetctfornodalstagingincervicalcancer